(NASDAQ:FIVE), PHILADELPHIA, PA, Dec. 22, 2025 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ: FIVE), the trend-right, high-quality extreme-value retailer for the kid and the kid in all of us, today announced that management is currently scheduled to host a fireside chat at the 2026 ICR Conference in Orlando, Florida, on Monday, January 12, 2026, at […]

(NASDAQ:AMRX), Approvals expand Amneal's biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug

(NASDAQ:BBIO), PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on December 18, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 9 new employees in restricted stock units

Five Below, Inc. Announces Participation in the 2026 ICR Conference GlobeNewswire December 22, 2025 PHILADELPHIA, PA, Dec. 22, 2025 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ: FIVE), the trend-right, high-quality extreme-value retailer for the kid and the kid in all of us, today announced that management is currently scheduled to host a fireside chat at

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia(R) and XGEVA(R) GlobeNewswire December 22, 2025 Approvals expand Amneal's biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group

Celularity Announces Closing of Financing Transactions GlobeNewswire December 22, 2025 FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 22, 2025 PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on December 18, 2025, the compensation committee of BridgeBio's board

Nova Minerals Limited Announces Closing of Public Offering GlobeNewswire December 22, 2025 Melbourne, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” and the “Company”) (Nasdaq NVA, NVAWW) (ASX: NVA), FRA: QM3)), a gold, antimony and critical minerals exploration stage company focused on advancing the Estelle Gold and Critical Minerals Project in Alaska,

H2O America Appoints Nicholas Whitley as Vice President of Business Development GlobeNewswire December 22, 2025 SAN JOSE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) — H2O America (NASDAQ: HTO), a leading investor-owned, pure-play water and wastewater utility, today announced the appointment of Nicholas Whitley as vice president of business development, effective December 22. In this role,

Atlas Welcomes Chris Robinson As Director of Nuclear Services With more than two decades of experience in the nuclear industry, Robinson will lead Atlas' Nuclear business, advancing safe and sustainable clean nuclear solutions. GlobeNewswire December 22, 2025 DENVER, Dec. 22, 2025 (GLOBE NEWSWIRE) — Atlas Technical Consultants (Atlas), a leading infrastructure and environmental solutions provider,